U.S. markets closed

Core One Labs Inc. (COOL.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.6900+0.1000 (+16.95%)
At close: 3:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5900
Open0.6300
Bid0.6700 x N/A
Ask0.6900 x N/A
Day's Range0.6300 - 0.6900
52 Week Range0.2900 - 1.7000
Volume622,794
Avg. Volume532,210
Market Cap48.968M
Beta (5Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-1.4170
Earnings DateMay 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • REPEAT - Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
      GlobeNewswire

      REPEAT - Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent

      VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”), a company operating under one of few Health Canada Controlled Drugs and Substances Dealer’s labs, is pleased to announce that it is in the final stages of completing its provisional patent application for the protection of its proprietary biosyntheti

    • Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
      GlobeNewswire

      Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent

      VANCOUVER, British Columbia, June 12, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”), a company operating under one of few Health Canada Controlled Drugs and Substances Dealer’s labs, is pleased to announce that it is in the final stages of completing its provisional patent application for the protection of its proprietary biosyntheti

    • ACCESSWIRE

      Core One Labs Provides Clarification on Trading Activity

      VANCOUVER, BC / ACCESSWIRE / May 21, 2021 /Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the "Company" or "Core One").